Highly active antiretroviral therapy (HAART) has changed the landscape
of human immunodeficiency virus (HIV) care in the developed world. Many patients
with access to antiretroviral therapy (ART) have benefited from the dramatic
reductions in mortality and morbidity, and HIV disease has become one of relative
chronicity for most but not all infected patients.1- 3
The success of HAART has now led to research into approaches to rid
virally suppressed patients of residual HIV reservoirs.4
Nonetheless, as with several chronic diseases, the treatment often has significant
adverse effects.5 This is the case with virtually
all drugs in the various classes of antiretroviral compounds approved by the
Food and Drug Administration.5 As such, physicians
have dealt with a pendulum effect in decisions regarding when to initiate
therapy during HIV infection.5- 7
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 11
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.